HomeProductsBioactive CompoundsPI3K/Akt/mTOR PathwaymTORPalomid 529
Chemical structure of CAS 914913-88-5

Palomid 529

CAS No.914913-88-5
MDL No.MFCD18633224
MFC24H22O6
MW406.40
InChI KeyYEAHTLOYHVWAKW-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.914913-88-5
Product NamePalomid 529

Biological Targets

MTOR

Associated Conditions

age-related macular degeneration
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences • Vol. 879, Issue 32 • 2011
PMID: 22100549DOI: 10.1016/j.jchromb.2011.10.028

The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.

Endocrine-related cancer • Vol. 18, Issue 4 • 2011
PMID: 21551258DOI: 10.1530/ERC-11-0045

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer.

British journal of cancer • Vol. 100, Issue 6 • 2009
PMID: 19240717PMC: PMC2661786DOI: 10.1038/sj.bjc.6604938

Documentation